Company Filing History:
Years Active: 2000
Title: The Innovations of Thomas D'Ambra
Introduction
Thomas D'Ambra is an accomplished inventor based in Rexford, NY (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of NPY antagonists. His work has led to the filing of one patent, showcasing his innovative approach to addressing complex medical challenges.
Latest Patents
D'Ambra's most recent patent focuses on NPY antagonists, which are compounds that inhibit the neuropeptide Y (NPY) signaling pathway. This innovation has potential applications in treating various conditions, including obesity and anxiety disorders. The patent reflects his commitment to advancing medical science through targeted research and development.
Career Highlights
Throughout his career, Thomas D'Ambra has been associated with Astra Aktiebolag, a prominent company in the pharmaceutical industry. His role at Astra has allowed him to collaborate with leading experts and contribute to groundbreaking research. D'Ambra's dedication to innovation has positioned him as a key figure in his field.
Collaborations
Some of D'Ambra's notable coworkers include Nils-Ånke Bergman and Garry M Pilling. Their collaborative efforts have fostered a dynamic research environment, leading to advancements in pharmaceutical development. Together, they have worked on various projects that aim to improve patient outcomes.
Conclusion
In summary, Thomas D'Ambra is a notable inventor whose work on NPY antagonists has the potential to impact the pharmaceutical landscape significantly. His contributions, along with his collaborations, highlight the importance of innovation in addressing medical challenges.